PMC:7784786 / 14097-14694 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"490","span":{"begin":189,"end":192},"obj":"Gene"},{"id":"491","span":{"begin":254,"end":257},"obj":"Gene"},{"id":"492","span":{"begin":347,"end":351},"obj":"Gene"},{"id":"493","span":{"begin":353,"end":358},"obj":"Gene"},{"id":"494","span":{"begin":360,"end":365},"obj":"Gene"},{"id":"495","span":{"begin":370,"end":375},"obj":"Gene"},{"id":"496","span":{"begin":206,"end":209},"obj":"Gene"},{"id":"497","span":{"begin":230,"end":238},"obj":"Species"},{"id":"498","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"499","span":{"begin":221,"end":229},"obj":"Disease"},{"id":"500","span":{"begin":506,"end":517},"obj":"Disease"},{"id":"501","span":{"begin":576,"end":588},"obj":"Disease"}],"attributes":[{"id":"A490","pred":"tao:has_database_id","subj":"490","obj":"Gene:923"},{"id":"A491","pred":"tao:has_database_id","subj":"491","obj":"Gene:923"},{"id":"A492","pred":"tao:has_database_id","subj":"492","obj":"Gene:3569"},{"id":"A493","pred":"tao:has_database_id","subj":"493","obj":"Gene:3458"},{"id":"A494","pred":"tao:has_database_id","subj":"494","obj":"Gene:7124"},{"id":"A495","pred":"tao:has_database_id","subj":"495","obj":"Gene:3605"},{"id":"A496","pred":"tao:has_database_id","subj":"496","obj":"Gene:7291"},{"id":"A497","pred":"tao:has_database_id","subj":"497","obj":"Tax:9606"},{"id":"A498","pred":"tao:has_database_id","subj":"498","obj":"MESH:C000657245"},{"id":"A499","pred":"tao:has_database_id","subj":"499","obj":"MESH:C000657245"},{"id":"A500","pred":"tao:has_database_id","subj":"500","obj":"MESH:D008231"},{"id":"A501","pred":"tao:has_database_id","subj":"501","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Several anticytokine therapies have been tried for treating the hyperinflammatory phase of COVID-19 [20,23–25]. Here, we report the use of a well-known anti-inflammatory antibody targeting CD6 to treat the CRS arising in COVID-19 patients. Using an anti-CD6 antibody could reduce the concentration of several pro-inflammatory cytokines, including IL-6, IFN-γ, TNF-α and IL-17, among others, representing an advantage as compared with single-cytokine targeting antibodies. The antibody would not exacerbate lymphopenia since it does not induce complement or antibody dependent cytotoxicity [10,11]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T51","span":{"begin":506,"end":517},"obj":"Phenotype"}],"attributes":[{"id":"A51","pred":"hp_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"Several anticytokine therapies have been tried for treating the hyperinflammatory phase of COVID-19 [20,23–25]. Here, we report the use of a well-known anti-inflammatory antibody targeting CD6 to treat the CRS arising in COVID-19 patients. Using an anti-CD6 antibody could reduce the concentration of several pro-inflammatory cytokines, including IL-6, IFN-γ, TNF-α and IL-17, among others, representing an advantage as compared with single-cytokine targeting antibodies. The antibody would not exacerbate lymphopenia since it does not induce complement or antibody dependent cytotoxicity [10,11]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T127","span":{"begin":0,"end":111},"obj":"Sentence"},{"id":"T128","span":{"begin":112,"end":239},"obj":"Sentence"},{"id":"T129","span":{"begin":240,"end":471},"obj":"Sentence"},{"id":"T130","span":{"begin":472,"end":597},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Several anticytokine therapies have been tried for treating the hyperinflammatory phase of COVID-19 [20,23–25]. Here, we report the use of a well-known anti-inflammatory antibody targeting CD6 to treat the CRS arising in COVID-19 patients. Using an anti-CD6 antibody could reduce the concentration of several pro-inflammatory cytokines, including IL-6, IFN-γ, TNF-α and IL-17, among others, representing an advantage as compared with single-cytokine targeting antibodies. The antibody would not exacerbate lymphopenia since it does not induce complement or antibody dependent cytotoxicity [10,11]."}